MATRIX FOR GUIDED WOUND CLOSURE

Wound closure matrix

PMI developed SUPRA SDRM®CW as a proven wound closure matrix optimized for the treatment of difficult-to-heal wounds. The product also contains SUPRA EPT™, the technology developed for SUPRATHEL®.

Pore size distribution

SUPRA SDRM®CW combines the benefits of SUPRATHEL®‘s microporous structure with additional larger pores which allow blood vessel ingrowth for the treatment of chronic and difficult-to-heal wounds.

SUPRA SDRM®CW has the ideal pore size distribution for rapid wound healing:
• The small pores (3-12 µm) support initial cell migration.1
• The large pores (50 – 600 μm) and high porosity lead to cell attachment and vascularization.2,3

Diabetic ulcer

Patient: Female, 40 years old
Etiology: Diabetic foot ulcer. Treated for 2 months with standard of care without success
Comorbidities: Diabetes mellitus

View case

Complex soft tissue defect

Patient: Male, 32 years old
Etiology: Trauma (sharp-blunt weapon; machete)
Comorbidities: None

View case

Grafting

Patient: Female, 60 years old
Etiology: Flame burn, 22 % TBSA, ABSI score 9
Comorbidities: None

View case

Indications

SUPRA SDRM®CW is indicated for use in the management of:

  • Venous ulcers
  • Arterial ulcers
  • Diabetic wounds
  • Mixed ulcers
0

Cell Migration

Ideal pore size distribution of SUPRA SDRM®CW for wound healing in µm. Pores greater than 50 µm promote vascularisation, while pores between 3 and 12 µm promote cell migration.1-3

0

SUPRA SDRM®CW

0

Collagen

Average number of weeks required to achieve complete healing with SUPRA SDRM®CW compared to collagen.4

0

SUPRA SDRM®CW

0

Collagen

Cumulative healing incidence of SUPRA SDRM®CW and collagen after 12 weeks.4

Composition

SUPRA SDRM®CW is a purely synthetic product and therefore does not bear any of the potential residual risks, that can occur with biological products of human or animal origin.PMI’s SUPRA EPT™ incorporates a unique and proprietary copolymer which leaves only CO2 and H2O as degradation products

SUPRA SDRM®CW contains a bimodal foam membrane structure, that, based on the literature, has the optimal combination of small and large pores – smaller pores promote cell migration while the larger, interconnected pores support vascularisation. This unique bimodal pore structure is a proprietary feature of PMI.

Polymer:
Lactide-base copolymer

Metabolism:
Hydrolytically (to CO2 and H2O)

Thickness:

1.5 – 2.1 mm

Sterilization:
Gamma sterilization

Porosity:

> 85%, pores 3 – 600μm

 

Clinically proven

In a recent prospective, randomised trial, SUPRA SDRM®CW led to faster healing rates compared to collagen dressings.(4)

• SUPRA SDRM®CW reduced the required time for wound healing of diabetic foot ulcers by 44% compared to
collagen-based dressings.
• Moreover, 90% of wounds treated were closed after 12 weeks compared to only 30% in the collagen group.

Support materials

Contact local representative for additional materials.

SUPRA SDRM®CW is available in many configurations to enable a customised treatment for different types of wounds in each patient.

1 Bruzauskaite et al. Cytotechnology. 2016 May;68(3):355-69 | 2 Chiu et al. Biomaterials. 2011 Sep;32(26):6045-51 | 3 Artel et al. Tissue Eng Part A. 2011 Sep;17(17-18):2133-41 | 4 Liden et al. Wounds. 2023 Aug;35(8):E257-60